On December 18, 2020 (Bangkok, Thailand), VenusA-Plus Transcatheter Aortic Valve Replacement System-Retrievable Delivery System (hereinafter referred to as "VenusA-Plus") developed by Venus Medtech (2500.HK) received approval from FDA Thailand, Ministry of Public Health. Following its launch in the Chinese market one month earlier, VenusA-Plus was granted a rapid approval by Thai authority.

VenusA-Plus retains the advantage of strengthened radial force of VenusA-Valve, first-generation TAVR product of the company, while thoroughly optimizing the delivery system and adding retrievable and repositionable features. VenusA-Plus underwent upgrades for better steerability, improving the success rate and outcomes of TAVR.

Venus Medtech possesses a comprehensive product layout in the TAVR field and provides integrated solutions encompassing "cerebral embolic protection-valvuloplasty balloon-heart valve ", demonstrating the strength of leading, innovative Chinese player in the interventional treatment of structural heart disease. Moving forward, Venus Medtech will redouble efforts to research, develop, and commercialize medical devices for structural heart disease treatment, providing safer solutions for doctors and patients around the world.